Similar articles

• Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

  Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD. Chu NV, et al. Diabetes Care. 2002 Mar;25(3):542-9. doi: 10.2337/diacare.25.3.542. Diabetes Care. 2002. PMID: 11874944 Clinical Trial.
• International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.

  Bloomgarden ZT. Bloomgarden ZT. Diabetes Care. 1998 Jun;21(6):1024-6. doi: 10.2337/diacare.21.6.1024. Diabetes Care. 1998. PMID: 9614626 No abstract available.
• Cardiovascular effects of troglitazone.

  Umland EM, Romanelli AM. Umland EM, et al. Ann Pharmacother. 1999 Feb;33(2):229-32. doi: 10.1345/aph.18028. Ann Pharmacother. 1999. PMID: 10084419 Review. No abstract available.
• Cardiac hypertrophy in diabetes patients with and without hypertension: effects of troglitazone, a novel antidiabetic drug, on diastolic function.

  Makino N, Hirayama H, Yonemochi H, Yano K, Abe N. Makino N, et al. Adv Exp Med Biol. 2001;498:143-8. doi: 10.1007/978-1-4615-1321-6_19. Adv Exp Med Biol. 2001. PMID: 11900362 Clinical Trial. No abstract available.
• Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.

  Marcus AO. Marcus AO. Diabetes Technol Ther. 2000 Summer;2(2):275-81. doi: 10.1089/15209150050025258. Diabetes Technol Ther. 2000. PMID: 11469270 Review.